Onzima Ventures PLC Update re Investment

 
TIDMONZ 
 
Onzima Ventures PLC 
 
                          ("Onzima" or the "Company") 
 
 N4 Pharma announces further patent filings for reformulation of Valsartan and 
                                   Losartan 
 
Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma"), its 
49%-owned investee company, has filed 17 novel patents for the reformulation of 
losartan and 12 novel patents for the reformulation of valsartan. 
 
This is in line with its strategy of filing strong broad patents for a range of 
drugs that it wishes to consider reformulating and are part of the suite of 
patents that N4 Pharma acquired from OPAL IP. 
 
N4 Pharma CEO Nigel Theobald commented:  "These are the first of a range of 
other reformulation patents we intend to file for a number of existing generic 
or soon to be generic drugs in addition to those already filed for Sildenafil. 
 
"We will continue to file strong life cycle management patents for a range of 
drugs over the coming weeks and months. Our initial formulation focus is still 
on our work for Sildenafil and we are now working with clinicians and 
formulators to decide which of these additional new drugs we will start 
reformulation work on next. 
 
"Sartans are the most recent class of anti-hypertensive agents and are 
extremely effective at relaxing smooth muscle in the arteries and thereby 
relieve hypertension. Since sartans are effectively metabolised by the body, 
the drug level is not effectively maintained in the body overnight which causes 
increased blood pressure on waking, resulting in potential patient health 
issues. 
 
"Our reformulation will look to maintain the dose more effectively overnight 
thereby reducing the nocturnal deficit of the drug and maintain low blood 
pressure throughout the drug dose, giving a unique clinical position in the 
sartans market which, in 2015, returned global sales of $11bn". 
 
For further information please contact: 
 
Onzima Ventures PLC                                                Tel:  +44 
(0) 1732 366 561 
 
Gavin Burnell, Luke Cairns 
 
Nominated Adviser 
 
Cairn Financial Advisers LLP                                     Tel:  +44 (0) 
20 7148 7900 
 
Sandy Jamieson, Liam Murray 
 
Broker 
 
Peterhouse Corporate Finance Limited                      Tel:  +44 (0) 20 7469 
0930 
 
Guy Miller, Lucy Williams 
 
 
 
END

(END) Dow Jones Newswires

July 11, 2016 06:06 ET (10:06 GMT)

Onzima Ventures (LSE:ONZ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024